RT Journal Article
T1 Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).
A1 Hermans, Lucas Etienne
A1 Svicher, Valentina
A1 Pas, Suzan Diepstraten
A1 Salpini, Romina
A1 Alvarez, Marta
A1 Ben Ari, Ziv
A1 Boland, Greet
A1 Bruzzone, Bianca
A1 Coppola, Nicola
A1 Seguin-Devaux, Carole
A1 Dyda, Tomasz
A1 Garcia, Federico
A1 Kaiser, Rolf
A1 Köse, Sukran
A1 Krarup, Henrik
A1 Lazarevic, Ivana
A1 Lunar, Maja M
A1 Maylin, Sarah
A1 Micheli, Valeria
A1 Mor, Orna
A1 Paraschiv, Simona
A1 Paraskevis, Dimitrios
A1 Poljak, Mario
A1 Puchhammer-Stöckl, Elisabeth
A1 Simon, François
A1 Stanojevic, Maja
A1 Stene-Johansen, Kathrine
A1 Tihic, Nijaz
A1 Trimoulet, Pascale
A1 Verheyen, Jens
A1 Vince, Adriana
A1 Weis, Nina
A1 Yalcinkaya, Tülay
A1 Lepej, Snjezana Zidovec
A1 Perno, Carlo
A1 Boucher, Charles A B
A1 Wensing, Annemarie M J
K1 antiviral drug resistance
K1 genotypic resistance testing
K1 hepatitis B virus
K1 nucleos(t)ide analogs
AB European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucleos(t)ide analogs (NAs) entecavir or tenofovir. However, many European CHB patients have been exposed to other NAs, which are associated with therapy failure and resistance. The CAPRE study was performed to gain insight in prevalence and characteristics of NA resistance in Europe. A survey was performed on genotypic resistance testing results acquired during routine monitoring of CHB patients with detectable serum hepatitis B virus DNA in European tertiary referral centers. Data from 1568 patients were included. The majority (73.8%) were exposed to lamivudine monotherapy. Drug-resistant strains were detected in 52.7%. The most frequently encountered primary mutation was M204V/I (48.7%), followed by A181T/V (3.8%) and N236T (2.6%). In patients exposed to entecavir (n = 102), full resistance was present in 35.3%. Independent risk factors for resistance were age, viral load, and lamivudine exposure (P  These findings support resistance testing in cases of apparent NA therapy failure. This survey highlights the impact of exposure to lamivudine and adefovir on development of drug resistance and cross-resistance. Continued use of these NAs needs to be reconsidered at a pan-European level.
YR 2015
FD 2015-06-23
LK http://hdl.handle.net/10668/9939
UL http://hdl.handle.net/10668/9939
LA en
NO Hermans LE, Svicher V, Pas SD, Salpini R, Alvarez M, Ben Ari Z, et al. Combined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE). J Infect Dis. 2016 Jan 1;213(1):39-48.
DS RISalud
RD Apr 19, 2025